Everest Medicines Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Everest Medicines Ltd. - overview
Established
2017
Location
New York, NY, US
Primary Industry
Biotechnology
About
Founded in 2017 and based in New York, US, Everest Medicines Ltd. operates as a biopharmaceutical company that develops drug candidates for oncology, immunology, cardio-renal disease, and infectious diseases. The company has raised a total of USD 310 millions of venture funding rounds. In October 2020, the company was listed on the Hong Kong stock exchange under the stock code 1952.
HK. The company's clinical and regulatory teams focus on licensing, developing, and commercializing innovative clinical-stage drug candidates, including Trodelvy, FGF401, Etrasimod, Nefecon, Xerava, VNRX-5133, and SPR206, a treatment for multi-drug resistant (MDR) Gram-negative bacterial infections. Everest Medicines Ltd. agreed with Spero Therapeutics to develop, manufacture, and commercialize SPR206, a treatment for MDR (multi-drug resistant) bacterial infections, in greater China, South Korea, and certain Southeast Asian countries.
Current Investors
CBC Group, Jiashan SDIC
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Bioinformatics, Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment, Cardiology, Pharmaceutical Research & Development
Website
www.everestmedicines.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.